title: In vivo regulation of dopamine and noradrenaline release by alpha2A-adrenoceptors in the mouse prefrontal cortex.
abstract: The present study investigated the role of alpha2A-adrenoceptor subtype in the regulation of noradrenaline and dopamine release in the medial prefrontal cortex. The effect of local introduction of the alpha2-adrenoceptor agonist dexmedetomidine (10-9-10-8 m) on noradrenaline and dopamine release was investigated in alpha2A-adrenoceptor knockout and control mice by using in vivo microdialysis. Furthermore, to reveal a possible distinction between regulation of baseline and peak release, we sampled the dialysate during both rest and handling-induced mild stress. Baseline noradrenaline and dopamine concentrations did not differ between alpha2A-adrenoceptor knockout and control mice. Dexmedetomidine decreased, in a concentration-dependent manner, noradrenaline and dopamine levels in both genotypes. However, the effect of dexmedetomidine on noradrenaline release was attenuated in the alpha2A-adrenoceptor knockout mice, whereas the effect on dopamine release did not differ between the genotypes. The first handling episode increased noradrenaline and dopamine levels to the same extent in both genotypes. However, in alpha2A-adrenoceptor knockout mice the noradrenaline and dopamine levels remained elevated in the samples following the first handling whilst, in the control mice, transmitter levels returned to baseline levels. In control mice the handling-induced peak noradrenaline and dopamine levels were lower after the administration of dexmedetomidine than during the first handling episode, but in alpha2A-adrenoceptor knockout mice no drug effect on handling-induced peak noradrenaline and dopamine levels was found. Our results suggest that the release of noradrenaline in the medial prefrontal cortex is mainly regulated via alpha2A-adrenoceptors, whilst other alpha-adrenoceptor subtypes play a significant role in the regulation of dopamine release.
authors.affiliation: Department of Neuroscience and Neurology, University of Kuopio, P.O. Box 1627, Finland. Jouni.Ihalainen@uku.fi
authors.forename: Jouni A
authors.initials: JA
authors.lastname: Ihalainen
authors.forename: Heikki
authors.initials: H
authors.lastname: Tanila
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D020927:Dexmedetomidine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005110:Extracellular Space / Q000378:metabolism; D005260:Female; D005838:Genotype; D006234:Handling, Psychological; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D017551:Microdialysis; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism*; D017729:Presynaptic Terminals / Q000187:drug effects / Q000378:metabolism*; D018341:Receptors, Adrenergic, alpha-2 / Q000172:deficiency* / Q000187:drug effects / Q000235:genetics; D015854:Up-Regulation / Q000187:drug effects / Q000235:genetics
chemical_list: C547769:Adra2a protein, mouse; D000316:Adrenergic alpha-Agonists; D018341:Receptors, Adrenergic, alpha-2; D020927:Dexmedetomidine